This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks.com featured highlights include NVIDIA, Insulet and Howmet Aerospace
by Zacks Equity Research
NVIDIA, Insulet and Howmet Aerospace have been highlighted in this Screen of The Week article.
Buy Profitable S&P 500 Stocks as the Index Tops 6000: NVIDIA & 2 More
by Tirthankar Chakraborty
NVIDIA, Insulet and Howmet Aerospace have been selected as the top picks with a high net income ratio.
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
PODD Stock Gains on Q3 Earnings and Revenue Beat, '24 Sales View Up
by Zacks Equity Research
Insulet's third-quarter performance benefits from the continued high demand for Omnipod 5.
Insulet (PODD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Insulet (PODD) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Insulet (PODD) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 16.88% and 4.90%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Aurora Cannabis Inc. (ACB) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Aurora Cannabis (ACB) delivered earnings and revenue surprises of 118.18% and 11.97%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Insulet Stock Gains From Expansion Strategies, Innovation
by Zacks Equity Research
PODD continues to drive increased awareness for Omnipod through its direct-to-consumer advertising campaign.
Stay Ahead of the Game With Insulet (PODD) Q3 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Insulet (PODD) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Owens & Minor (OMI) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 5% and 1.25%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of 33.33% and 4.35%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Is Insulet Stock a Smart Addition to Your Portfolio Right Now?
by Zacks Equity Research
PODD continues to make strides with Omnipod 5 and its market expansion. Robust solvency is a plus.
PAHC vs. PODD: Which Stock Is the Better Value Option?
by Zacks Equity Research
PAHC vs. PODD: Which Stock Is the Better Value Option?
Profitable S&P 500 Stocks to Buy in a Strong Q4: NVIDIA & 2 Others
by Tirthankar Chakraborty
NVIDIA, Insulet and Monolithic Power Systems have been selected as the top picks with a high net income ratio.
HLN or PODD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HLN vs. PODD: Which Stock Is the Better Value Option?
BAX vs. PODD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BAX vs. PODD: Which Stock Is the Better Value Option?
Should You Continue to Retain PODD Stock in Your Portfolio Now?
by Zacks Equity Research
Insulet's Omnipod 5 is set to drive growth in the upcoming quarters. Meanwhile, the stock is facing challenges due to economic uncertainties.
Insulet's Omnipod 5 Wins FDA Approval for Type 2 Diabetes
by Zacks Equity Research
PODD marks a major milestone with Omnipod 5 approval for the treatment of type 2 diabetes.
Illumina (ILMN) Beats on Q2 Earnings, Lowers 2024 Sales View
by Zacks Equity Research
Illumina's (ILMN) Q2 earnings and revenues surpass estimates in a challenging global macroeconomic environment.
Insulet (PODD) Q2 Earnings Miss Estimates, '24 Sales View Raised
by Zacks Equity Research
Insulet's (PODD) second-quarter performance benefits from the continued high demand for Omnipod 5.
Insulet (PODD) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Insulet (PODD) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Insulet (PODD) Q2 Earnings Miss Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of -3.51% and 5.48%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Unlocking Q2 Potential of Insulet (PODD): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Insulet (PODD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Insulet (PODD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.